Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cancer Rep (Hoboken) ; 5(10): e1654, 2022 10.
Artigo em Inglês | MEDLINE | ID: mdl-35715880

RESUMO

BACKGROUND: Patients with unresectable or metastatic differentiated thyroid carcinoma (DTC) are rare and require individualized therapy. This may require approaches not typically used in resectable disease. We report a patient treated with lenvatinib and external beam radiation therapy. CASE: An 87-year-old woman presented with cT4N1aM1 papillary thyroid carcinoma with tracheal invasion. She was not a candidate for surgery, radioactive-iodine, or radiation, so a trial of lenvatinib was offered. Her tumor showed clinical, biochemical, and radiological response after 5 months of lenvatinib, and she subsequently received external beam radiation. She enjoys good quality of life without evidence of cancer progression off therapy 21 months post-initiation of treatment. CONCLUSION: Lenvatinib may be effective in RAI-naïve advanced DTC patients as a component of individualized multimodal therapy when conventional options are not feasible.


Assuntos
Adenocarcinoma , Antineoplásicos , Neoplasias da Glândula Tireoide , Adenocarcinoma/tratamento farmacológico , Idoso de 80 Anos ou mais , Antineoplásicos/uso terapêutico , Feminino , Humanos , Radioisótopos do Iodo/uso terapêutico , Compostos de Fenilureia , Qualidade de Vida , Quinolinas , Neoplasias da Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...